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Abstract
Background: In the last 20–30 years, many international studies have found substantial differences in the use
of (older) psychotropic medication between European countries. The majority mentioned an important role for
attitudes and beliefs towards psychotropic medication. So far, no studies have looked into the effects of cultural
diversity on the use of new medications entering the market. As national cultures relate deeply to held values
regarding, for example, what is seen as effective versus ineffective or safe versus dangerous, (cultural) diversity in
decision making around the role of new medications in clinical practice may already be expected from the first day
after market authorization.
Methods: This study examined the relation between cultural diversity, described in Hofstede’s model of cultural
dimensions (Power Distance, Individualism, Masculinity, Uncertainty Avoidance, Indulgence and Long-Term
Orientation) and utilization of three new psychotropic medications, namely aripiprazole, duloxetine and pregabalin
in Europe. Country level sales data of the case study medications were correlated to country-specific scores of
Hofstede’s cultural dimensions. IMS Health’s MIDAS database has been used for sales data (converted to Defined
Daily Doses/1000 inhabitants/day) for the case study medications from the market authorization date in 2004 until
December 2009 for 23 EU member states.
Results: Consumption of the case study medications was seen in all countries. In general, pregabalin was used
more often than aripiprazole and duloxetine. In 2 years after market authorization, approximately 80% of all
countries have reported use of all three molecules.
Correlations between Hofstede dimensions individualism, long-term orientation and indulgence and total use of
the case study medications tended to become stronger over time, but they were only statistically significant for
indulgence at two years after market authorization (rho = 0.51, p = 0.014) and three years after market authorization
(rho = 0.54, p = 0.008). A more detailed analysis showed (slight) variation by molecule.
Conclusions: This study is a first step in including cultural dimensions when explaining cross-national variation
in the use of new medications. The results indicate that indulgence, however marginally, is a cultural aspect that
relates to the utilization of new psychotropic medications, suggesting that within the cultural context, less
regulation of social norms is a main factor in explaining cross-national variation in uptake of these medications.
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Background
Great differences, as well as startling similarities, can be
seen when comparing global cultures. People around the
globe are similar in their essential humanity: we commu-
nicate with each other, we sustain ourselves with food,
and when we sleep we often dream. Yet we speak differ-
ent languages, eat different foods, and dream different
dreams. These are some examples of cultural diversity
[1]. Culture can provide us with many answers on how
and why people behave differently around the globe
thereby bringing their own perspectives and values to
the health care system [2, 3]. Medical care is strongly
influenced by cultural norms and values ingrained over
hundreds of years. Differences can show up in the types
and quantities of medications doctors prescribe, the
kinds and numbers of operations performed, even what
blood pressure levels are thought to require treatment
[4]. Cultural factors are therefore likely to play a role in
explaining international variation in health care use,
including utilization of medications [5]. Studies have
already shown the relevance of cultural diversity in the
use of antibiotics [6, 7]. These studies showed that the
cross-national differences in use of antibiotics in ambu-
latory care are potentially explained by national cultural
differences resulting from varying perceptions and influ-
ences. Psychotropic medication is another area where
differences in medication use across Europe seem to be
related to cultural diversity [8, 9]. In the last 20–30 years,
many international studies have found substantial differ-
ences in the use of psychotropic medication among
European countries [10, 11]. An important role for atti-
tudes and beliefs towards psychotropic medication was
found in those studies focusing on explanations of these
differences. An international perspective on pediatric
psychopharmacology (2008) stated “the cultural context
seems to exert a greater influence on the identification
and management of psychiatric disorders than on other
areas of medication”[12].
The impact of cultural diversity might be foreseen in
‘older’ products. This is possible due to the relatively
long existence and the embedment of these medications
in clinical practice. However, little is known about the
relevance of cultural diversity for products that recently
received a market authorization. So far, no studies have
looked into the effects of cultural diversity on the use of
new medications entering the market. It is well known
that new pharmacological therapies are challenging
healthcare systems. There is an increasing need to assess
their therapeutic value in relation to existing alternatives
as well as their potential budget impact. [13]. Assessment
of the effectiveness compared with alternative treatment(s)
already plays an important role in many European mem-
ber states in determining the reimbursement status of
new medications [14]. However, as national cultures
deeply relate to held values regarding, among others, what
is seen as effective versus ineffective, safe versus danger-
ous, rational versus irrational and expensive versus inex-
pensive, diversity in decision making around the role of
new medications in clinical practice may already be deter-
mined from the date of market authorization (MA). For
the purpose of this study, three new psychotropic medica-
tions that were approved via the EU centralized procedure
in 2004, have been selected. These medications were aripi-
prazole (Abilify®), duloxetine HCl (Cymbalta®/Xeristar®),
and pregabalin (Lyrica®), which are (commonly) used in
the treatment of schizophrenia, bipolar disorder, anxiety,
and major depression [15–17]. These medications were
selected because despite being clinically relevant for some
patients, they are not seen as indisputable medical break-
throughs within their therapeutic areas. Nevertheless, they
also can’t be seen, nor are they priced, as simply ‘me-too’
drugs. Variation in use (and effectiveness) of these medica-
tions between patients or between prescribers, and on a
higher level between regions and countries, is therefore
likely to be influenced by different cultural approaches in
the utilization of these medications [12, 18].
The aim of the study was to assess the relation be-
tween cultural diversity and utilization of these three
new medications in Europe. The utilization of these
medications over time was studied (up to three years
after MA) to see whether the effect of cultural diversity
varied following the settlement of the new medications
on the European market.
Theoretical background
Cultural dimensions and expectations towards use of
aripiprazole, duloxetine and pregabalin in EU member states
The effect of cultural dimensions is complex. It influ-
ences a multitude of social phenomena on the macro,
such as patterned relations between large social groups,
and micro level, e.g. the behavior of individualistic mem-
bers of the society. The dynamic nature of culture con-
veys the top-down and bottom-up processes where one
cultural level affects changes in other levels of culture
[19]. Macro-level systems appear increasingly likely to in-
fluence the nature of micro-level interaction. Reciprocally,
behavioral changes at the individual level, through
bottom-up processes, become shared behavioral norms
and values, modifying the culture of a macro level entity
[19, 20]. Coleman’s scheme of the micro-macro linkage is
one of the most useful expository vehicles for thinking
about multi-level issues in social science research [20]. It
indicates the relationship between macro factors (e.g.
institutions) and the micro factors that underlie their
causal relation (values, economic behavior). Most of the
research on culture has focused on identifying the core
cultural values that differentiate cultures on a macro level.
An example of a popular and validated approach is
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Hofstede’s model of cultural dimensions [21]. He distin-
guished six dimensions along which cultural values can be
compared with other cultures: individualism-collectivism;
uncertainty avoidance; power distance (strength of social
hierarchy); masculinity-femininity (task orientation versus
person-orientation); long term-short term orientation and
indulgence-restraint (see Table 1) [22]. As Hofstede trans-
formed the concept of culture into quantifiable measures,
it can be used in cross-national country comparative
studies [6, 7].
Based on Hofstede’s model of cultural dimensions, we
assume the following relation between these cultural
dimensions and the use of aripiprazole, duloxetine and
pregabalin.
Power distance refers to ‘preferences of how persons
with a different (social) status communicate with each
other’. Albeit patient empowerment is a topic of interest
in current health care, the asymmetry in status between
doctors and patients remains persistent [23]. Still coun-
tries differ in their power distance and Deschepper et al.
(2008) showed that power distance was positively
correlated to the use of antibiotics [6]. They stated that
in countries with a low power distance, a preference for
deliberation about the use and perception of antibiotics
between patients and doctors might affect the prescrip-
tion of antibiotics [6]. Furthermore, low country scores
on Power Distance may have implications for collabor-
ation between doctors and other health care profes-
sionals, resulting in exchange of information about
(optimal) medications therapy. This same phenomenon
can be expected to occur with the utilization of other
medications. A preference for discussion about the use
and perception of new CNS medications might be
favored in countries with a low power distance leading
to lower use as contrasted with a ‘doctor knows best’
attitude in countries scoring high for power distance.
Individualism concerns with ‘the degree to which indi-
viduals are integrated into groups or not’. Previous litera-
ture indicates that people from individualist cultures are
more likely to tolerate diversity and deviation from the
norm because such cultures are extremely fragmented,
with extensive individuality, due to the desirability of per-
sonal goals. Individuals are therefore less likely to be part
of a group [21, 24, 25]. Diseases interfering with the CNS
are more likely to cause behavior deviated from the norm.
In individualistic countries CNS patients may be less stig-
matized and access to appropriate services and/or use of
CNS medication might be more common [24].
Masculinity can be defined as ‘the distribution of emo-
tional roles between the genders’ and is expected to have
contradictory effects on the use of these three medica-
tions. On the one hand, countries with a masculine cul-
ture may be expected to correlate negatively with the
use of CNS medications, e.g. because these countries
value a “live to work” ethic, rather than a “work to live”
ethic, value ‘things’ more important than ‘quality of life’,
are ego orientated and failing is seen as a disaster. On
the other hand, these countries are strongly result
oriented which hypothetically may lead to a quicker ini-
tiation of treatment in order to overcome negative
effects of the disease and thus to a higher level of use.
Uncertainty avoidance has to do with ‘a society's toler-
ance for uncertainty and ambiguity’. In countries with
high uncertainty avoidance more CNS medications may
be used because doctors and societies want to avoid un-
structured situations (behavior different from usual) in
cases of severe CNS disorders. However, because these
are new medications related to uncertainty and ambigu-
ity with regard to effectiveness, long term side effects,
and/or cost-effectiveness, doctors and patients might be
less willing to use these medications compared to older,
more commonly used medications in countries with a
strong uncertainty avoidance. However, it should be kept
in mind that uncertainties about the effectiveness of
those medications may also exist.




Power distance (PDI) relates to the extent to which the less powerful
members of a society accept and expect that power is distributed
unequally. It suggests that a society’s level of inequality is endorsed
by the followers as much as by the leaders [7].
Power distance is hypothesized to be positively associated with the use
of the case study medications.
Individualism (versus collectivism) (IDV) A society’s position on this
dimension is reflected in whether people’s self-image is defined in
terms of “I” (individualism) or “we” (collectivism).
Individualism is hypothesized to be positively associated with the use
of the case study medications.
Masculinity (versus femininity) (MAS) refers to the distribution of
emotional roles between the genders. The masculinity side of this
dimension represents a preference in society for achievement, heroism,
assertiveness and material reward for success. Society at large is more
competitive.
Masculinity is hypothesized to have no effect on the use of the case
study medications.
Uncertainty avoidance (UAI) indicates the degree to which the
members of a society feel uncomfortable with uncertainty and
ambiguity, and shows how comfortable society is in unstructured
situations that are novel, unknown and surprising.
Uncertainty avoidance is hypothesized to have no effect on the use of
the case study medications.
Long-term (versus short-term orientation) (LTO) fosters pragmatic
virtues oriented towards future rewards, in particular saving,
persistence and adaptation to changing conditions.
Long-term orientation is hypothesized to be negatively associated with
the use of the case study medications.
Indulgence (versus Restraint) (IVR) Indulgence stands for a society that
allows relatively free gratification of basic and natural human drives
related to enjoying life and having fun.
Indulgence is hypothesized to be positively associated with the use of the
case study medications.
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Long-term orientation indicates the extent to which a
society focuses on the future instead of the present only.
Countries with a short-term orientation are normative in
their thinking but also have a focus on achieving quick
results whereas societies with a long term orientation
show perseverance in achieving results. In addition, coun-
tries with a short term orientation may adapt to changes,
such as the introduction of new medications, more rapidly
than countries with a long term orientation, resulting in a
higher use of these new CNS medications.
Indulgence is the feature of a society that allows satis-
fying, relatively free, feelings and desires.
The opposite is restraint which stands for a society that
‘suppresses gratification of needs and regulates it by means
of strict social norms‘[21]. Indulgence can be expected to
relate positively with the use of CNS medications, as these
medications may have a rewarding effect on patients and
the incentive of discontinuation might therefore be
lacking. Countries with a high level of restraint might sup-
press the use of these new medications. Stricter regula-
tions in these societies are either due to the higher
treatment costs associated with the use of these medica-
tions and/or little additional therapeutic value or due to
the risk of dependence.
Based on these hypotheses we expect that power dis-
tance, individualism, long-term orientation and indul-
gence may be correlated with the consumption of
aripiprazole, duloxetine and pregabalin. For a summary
of the hypotheses, see Table 1.
Methods
Data source
IMS Health’s MIDAS database was used as the source of all
sales data for aripiprazole, duloxetine and pregabalin from
the market authorization date in 2004 until December
2009. MIDAS is a summary of data obtained from IMS
Health’s detailed audits of pharmaceutical purchases made
by retailers (in 70 countries) and hospitals (in 45 countries).
MIDAS contains information on sales of individual prod-
ucts, measured in both currency and physical units, as well
as information on the product manufacturer, active ingredi-
ent, brand, form, strength, pack size, and therapeutic class.
Data used in this analysis cover sales to the retail phar-
macy sector. Sales data include direct sales by suppliers
to pharmacies and indirect sales via wholesalers. The
retail pharmacy sector accounts for most sales in all of
the countries considered in the analysis. Data were ob-
tained for all EU member states (per 01/05/2004), except
for the Mediterranean islands of Malta and Cyprus.
According to Dutch law, ethics approval was not
applicable because the study involves no patient data
(Medical Research (Human Subjects) Act).
Data on cultural dimensions were obtained from Hofstede
[21]. Putting together national scores (from 1 for the lowest
to 112 for the highest), Hofstede’s model allows international
comparison between cultures using six cultural value dimen-
sions (see Table 1) [22]. Scores are based on the analysis of a
large database of employee value scores collected within
various respondent groups such as employees of IBM (more
than 50 countries), commercial airline pilots and students in
23 countries and civil service managers in 14 counties.
In 2010, scores on the dimensions were listed for 76
countries. The country scores on the dimensions are rela-
tive and can be assessed from: http://geerthofstede.com/
research-and-vsm/dimension-data-matrix/. These dimen-
sions have been replicated in a number of successive stud-
ies by different researchers using a variety of other
matched samples of respondents [26]. Both studies that
have assessed the relevance of cultural characteristics in
explaining variation in the use of antibiotics, have used
Hofstede’s theory of cultural dimensions [6, 7]. These
dimensions furthermore provide a relatively general
framework for analysis that can be easily applied because
it reduces the complexities of culture and its effects on
behavior into quantifiable dimensions [7]. Country scores
for Hofstede dimensions as presented in ‘Cultures and
Organizations 3rd edition 2010’ were available for all
countries for which IMS provided utilization data [27].
Data measurement
Volume was used as the measure of consumption and
was expressed in the World Health Organization defined
daily dose (DDD). The DDD is the assumed average
maintenance dose per day for a medication used for its
main indication in adults [28]. To allow for different
population sizes, volume was expressed per 1000 inhabi-
tants. Volume data were obtained on a quarterly level.
Population statistics on number of inhabitants were ob-
tained from the website of the United Nations, Department
of Economic and Social Affairs for 2009 [29].
Data analysis
For each quarter following the date of market authorization,
it was assessed how many countries showed an uptake of
aripiprazole, duloxetine or pregabalin. Uptake was present if
the level of use was higher than 0.01 DDDs/1000inhabi-
tants/day (arbitrary cut off point). The percentage of coun-
tries with adoption of the new medication could then be
calculated and reflected in the adoption curve as shown in
Fig. 1.
Spearman correlation coefficient rho was used to calcu-
late correlations between the total usage level of aripipra-
zole, duloxetine and pregabalin per country at various
moments in time and country scores of Hofstede dimen-
sions. Usage level was defined as the level of utilization in
DDDs/1000inhabitants/day in a certain quarter and year.
A p-value of 0.05 or smaller was considered significant.
To limit the influence of possible national system level
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factors, such as differences in time to reimbursement deci-
sion or national decisions about the uptake of the new
medications in clinical guidelines, t = 0 was set country
specific. In other words, t = 0 was set at the moment the
first usage was seen in a country. This first usage can fol-
low directly after MA or may be delayed due to one or
more of the examples mentioned above. Stratified analyses
were conducted by studying each molecule separately. As
utilization of medications may vary with national wealth
as expressed by gross domestic product (GDP), potential
effects were examined by calculating the partial correla-
tions controlled for GDP per capita and then compared
with the unadjusted correlations.
Results
Consumption of the case study medications was seen in
all countries. One year after uptake, total utilization of
aripiprazole, duloxetine and pregabalin ranged between
0.4 and 344.2 DDDs/1000inhabitants/year (Poland and
Spain, respectively). This increased to range 19.0–562.1
DDDs/1000inhabitants/year (Poland and Spain, respect-
ively), three years after uptake (see Table 2). In general,
duloxetine was used more often than aripiprazole and
pregabalin. Volume used in DDDs (in millions) was 1.1
(2004) to 222.1 (2009) for pregabalin, 4.2 (2004) to 256.1
(2009) for duloxetine and 1.4 (2004) tot 65.1(2009) for
aripiprazole. The adoption curve (see Fig. 1) shows a
similar pattern for all three molecules, i.e. 2 years after
market authorization, approximately 80% of all countries
reported use of all three molecules, with pregabalin hav-
ing a slightly faster adoption compared to the other two
medications.
Variations can be seen between the level of usage over
time for the various EU member states (Table 2). Both
Spain and France had a relatively high level of use one
year after uptake. After three years of uptake, Spain
remained to have a relatively high level of use, closely
followed by Belgium, which had a relatively low con-
sumption one year after market uptake. This same pat-
tern (relatively low uptake after one year and a relatively
high uptake after three years) can be seen for a country
like Portugal, and to a lesser extent Greece.
Country scores on the Hofstede dimensions clearly
varied across all countries (Table 2). Of all dimensions,
masculinity was found to have the largest range (5–110)
and long-term orientation the lowest range (24–83)
between the studied countries. Correlations between
Hofstede dimensions individualism, long-term orienta-
tion and indulgence and total use of aripiprazole, dulox-
etine and pregabalin tended to become stronger over
time, but they were only statistically significant for in-
dulgence at t = 2 (rho = 0.51, p = 0.014) and t = 3
(rho = 0.54, p = 0.008), see Table 3. When controlling
the correlations between Hofstede dimensions and the
total use of aripiprazole, duloxetine and pregabalin for
wealth, Hofstede dimension indulgence remained signifi-
cant (rho = 0.33, p = 0.007).
A more detailed analysis showed (slight) variation by
molecule (see Fig. 2a-c). Stratified analysis revealed posi-
tive significant correlations for indulgence (at t = 1, 2
and 3) and a negative significant correlation for long
term orientation at t = 3 with the use of aripiprazole.
Furthermore, negative significant correlations were
found for long term orientation (at t = 0, 2 and 3) with
Fig. 1 Adoption curve of the three case study medications included in the present study
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the use of duloxetine and a positive significant correlation
at t = 1 and t = 3 for uncertainty avoidance. Positive sig-
nificant correlations were also found for pregabalin and
the cultural dimension indulgence at t = 2 and 3. A nega-
tive significant correlation was found at t = 0 for power
distance and the use of pregabalin. Long term orientation
was found to correlate mostly negative with the use of all
case study medications (although not always significant).
Indulgence was found to have the highest positive correl-
ation for both aripiprazole and pregabalin, but not for
duloxetine. Over time most of Hofstede dimensions corre-
lated only slightly with the three case study medications.
Especially in the case of pregabalin, most correlation
trends over time tend off to zero.
Discussion
This study assessed the relation between cultural diver-
sity and utilization of three new psychotropic medica-
tions in Europe. The utilization of these medications
over time was studied up to three years to explore
Table 2 Total use of the case study medications and country scores on Hofstede dimensions
Total use of the case study medications in DDDs/1000inhabitants/year Country scores
Country t = 0 t = 1 t = 2 t = 3 PDI IDV MAS UAI LTO IVR
Austria 8.9 52.0 101.6 214.5 11 55 79 70 60 63
Belgium 4.0 253.4 426.6 506.1 65 75 54 94 82 57
Czech Republic 0.5 30.7 53.6 56.5 57 58 57 74 70 29
Denmark 26.8 146.1 232.2 341.2 18 74 16 23 35 70
Estonia 10.9 33.7 52.3 45.7 40 60 30 60 82 16
Finland 2.9 123.5 269.7 452.3 33 63 26 59 38 57
France 46.0 230.9 184.8 239.9 68 71 43 86 63 48
Germany 3.8 133.7 201.9 262.3 35 67 66 65 83 40
Greece 13.9 142.4 332.3 494.9 60 35 57 112 45 50
Hungary 5.1 80.4 118.2 169.8 46 80 88 82 58 31
Ireland 8.8 152.4 254.5 350.7 28 70 68 35 24 65
Italy 6.8 127.4 203.6 262.9 50 76 70 75 61 30
Latvia 2.3 31.2 51.0 48.4 44 70 9 63 69 13
Lithuania 1.2 59.1 101.3 92.7 42 60 19 65 82 16
Luxembourg 11.0 226.1 353.2 455.2 40 60 50 70 64 56
Netherlands 5.4 91.5 138.5 176.1 38 80 14 53 67 68
Poland 0.0 0.4 10.2 19.0 68 60 64 93 38 29
Portugal 3.4 181.4 340.5 440.5 63 27 31 104 28 33
Slovak Republic 3.2 58.2 96.20 140.8 104 52 110 51 77 28
Slovenia 2.5 158.3 282.9 356.3 71 27 19 88 49 48
Spain 41.5 344.2 464.2 562.1 57 51 42 86 48 44
Sweden 0.9 76.5 202.7 336.1 31 71 5 29 53 78
United Kingdom 2.4 78.7 141.7 184.7 35 89 66 35 51 69
PDI power distance, IDV individualism, MAS masculinity, UAI uncertainty avoidance, LTO long-term orientation, IVR indulgence
t = 0: the moment first usage was seen, t = 1: one year after first usage was seen, t = 2: two years after first usage was seen and t = 3: three years after first usage
was seen
Table 3 Correlations between the total use of the case study
medications and Hofstede dimensions
Cultural
dimensions
Spearman correlation coefficient (Rho)
(p-value)

















































PDI power distance, IDV individualism, MAS masculinity, UAI uncertainty
avoidance, LTO long-term orientation, IVR indulgence
*= statistically significant (p < 0.05)
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whether the effect of cultural diversity on the total use
of these new medications varied following the settlement
(e.g. embedment in guidelines, reimbursement issues) of
these medications on the European market.
Although homogeneity in the uptake (availability) was
seen between the three molecules, large cross-national
variation was seen in the level of use between one and
three years after the first date of usage seen in a country.
This variation came not as a surprise as many previous
studies have shown consistent significant cross-national
variation in older psychotropic medications utilization
[8–11]. However, none of these studies linked cultural
diversity to the level of use of the medications included
in the studies.
The findings of a positive correlation for CNS medica-
tion use with indulgence corroborate our hypothesis
with regard to this dimension and showed that (although
limited) cultural diversity plays a role in the level of use
of the case study medications. If we apply restraint to
medical situation and decision making, policy makers
and/or physicians may suppress the use of new medica-
tions, especially when treatment costs are higher and
added therapeutic value is unknown compared to the
already existing options and positive effects may vary be-
tween individuals. Criteria for cost-effectiveness are used
for reimbursement decision in most European countries
[30]. The dimension long term orientation showed a
negative trend as hypothesized. Relevant elements of this
dimension, such as social consumption and spending
seem to exert a role in the consumption of new medica-
tions [21]. However, correlations were not found to be
significant with total use of the case study medications.
The trends for Hofstede dimensions ‘power distance’
and ‘masculinity’ started positive, but trended off to zero.
DeSchepper et al. (2008) showed that power distance
was positive correlated with the use of antibiotics sug-
gesting that the cultural-specific way people deal with
authority is an important factor in explaining cross-
national differences in antibiotics use [6]. Perhaps, due
to the novelty of these medications, cultural diversity in
power distance has not yet shown to have an effect on
the use of new medications. Finally, our hypothesis was
confirmed for Hofstede dimension uncertainty avoidance
(no effect on case study medications) but not confirmed
for Hofstede dimension Individualism. The (slight) vari-
ation between the three case study medications further-
more shows the importance of stratified analyses. After
all, when developing specific policies, it may be import-
ant to know which cultural dimension may play a role in
the utilization of the medication.
This study has some limitations. The number of coun-
tries is (still) limited and the study may therefore be
underpowered to detect significant differences between
countries. The IMS data used in this study are sales data
from the retail pharmacy sector. Any inpatient use of
these medications is not included in the study. However,
the bulk of the products is used in the outpatient sector.
Whether the results found in this study may be due to
Fig. 2 a Correlations between aripiprazole and Hofstede dimensions over time. Marked dots show statistically significant correlations.
PDI = power distance, IDV = Individualism, MAS = masculinity, UAI = uncertainty avoidance, LTO = long-term orientation, IVR = indulgence. b
Correlations between duloxetine and Hofstede dimensions over time. Marked dots show statistically significant correlations. PDI = power distance,
IDV = Individualism, MAS = masculinity, UAI = uncertainty avoidance, LTO = long-term orientation, IVR = indulgence. c Correlations between
pregabalin and Hofstede dimensions over time. Marked dots show statistically significant correlations. PDI = power distance, IDV = Individualism,
MAS = masculinity, UAI = uncertainty avoidance, LTO = long-term orientation, IVR = indulgence
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the fact that cultural diversity does not play an import-
ant role in explaining cross-national variation in new
psychotropic medication use, or that Hofstede’s model is
unsuitable for new medications just entering the market
remains unanswered. Hofstede’s model is based on the
analysis of employees of IBM, commercial airline pilots,
students and civil service managers. One could argue
whether the scores based on these groups are represen-
tative and valid for prescribers and users of these medi-
cations. However, Hofstede’s model is the model most
validated by research, based on rigorous cultural re-
search [31]. It is also the most widely cited model and
his observations and analyses provide researchers with
highly valuable insights into the dynamics of cross-
cultural diversity [31]. The model however, has not been
without criticism, notably by Bhimani (1999), Harrison
& McKinnon, (1999) and McSweeny (2002) [32–34].
Critiques of Hofstede’s model are mainly related to the
quantitative nature of his research. For the purpose of
this study, the key critique comes from Smith (2002)
who argues that “…if we compare culture A and culture
B on some attribute, the mean scores (macro level) that
we achieve will tell us nothing about variability within
each nation, nor will it tell us whether the particular
individuals (micro level) whom we sampled are typical
or atypical of that culture” [35].
Besides cultural values, other determinants play a role
when explaining variation in medication use such as ac-
cess to specialists, country’s wealth, marketing by pharma-
ceutical companies, differences in the types and quantities
of medicines doctors prescribe, level of co-payment and
date and outcome of reimbursement decisions [5]. When
adjusting the correlations between Hofstede dimensions
and the total use of aripiprazole, duloxetine and pregaba-
lin for wealth, Hofstede dimension indulgence remained
significant. To limit the possible effect of the moment of
reimbursement decision we set t = 0 at the moment the
first usage was seen in a country. As these medications
were approved via the EU centralized procedure, no differ-
ences in market authorization dates could exist between
the various countries. Unfortunately, other determinants
are not (easily) measurable or available. Our limited sam-
ple size and use of a nonparametric approach precluded
the possibility of a more fine-grained analysis involving
other/multiple values that determine medication use.
Despite these limitations, we do believe that cultural di-
mensions as presented by Hofstede are a (simple but) useful
tool to measure the extremely complex concept of culture.
They may offer an opportunity to improve our understand-
ing of the remarkable and unexplained cross-national vari-
ation in medication use, even for medications just entering
the market. As a country’s culture is an important factor
within a health care system, it should also be considered
when explaining cross-national variation in the use of new
medications. After all, benchmarking the level of medica-
tion use against a country with a dissimilar culture may be
ineffective.
Nevertheless, more cross-national comparative research,
and the availability of larger data sets including data on an
individual level, is needed to better understand the rela-
tionship between cultural diversity and the use of (new)
medications. As decision making never occurs in a ‘cul-
tural vacuum’: one cannot simply transplant a policy
measure from one country to another without paying at-
tention to cultural aspects. Furthermore, the chance of
(new) policies being implemented is more likely when
there is sufficient base of public support.
Conclusions
In conclusion, this study is a first step in including cul-
tural dimensions when explaining cross-national vari-
ation in the use of new medications. The results indicate
that indulgence, however marginally, is a cultural aspect
that relates to the utilization of new psychotropic medi-
cations, suggesting that within the cultural context, less
regulation of social norms is a main factor in explaining
cross-national variation in uptake of these medications.
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